Literature DB >> 12111201

Cell proliferation and apoptosis in human uterine leiomyomas and myometria.

Darlene Dixon1, Gordon P Flake, Alicia B Moore, Hong He, Joseph K Haseman, John I Risinger, Johnathan M Lancaster, Andrew Berchuck, J Carl Barrett, Stanley J Robboy.   

Abstract

To determine the role of cell proliferation and apoptosis in uterine leiomyoma growth, we studied protein expression of two major regulatory proteins of apoptosis -- Bcl-2 (anti-apoptotic) and Bax (pro-apoptotic) -- and two endogenous markers of cell replication - proliferating cell nuclear antigen (PCNA) and Ki-67 - in tumors and matched myometrium from premenopausal women. Conventional mitotic indices also were determined, and all proliferation data were correlated to tumor size. In situ end-labeling of fragmented DNA and routine histology were used to assess apoptosis. Our results showed that the apoptosis-regulating proteins (Bcl-2 and Bax) were expressed in the cytoplasm of the leiomyoma and myometrial smooth muscle cells throughout the menstrual cycle. Bax expression differed from Bcl-2 in that it also was found in the cytoplasm of vascular smooth muscle cells of the myometria and tumors. Both tumors and myometrial samples expressed 26-kDa and 21-kDa proteins that reacted with antibodies directed towards Bcl-2 and Bax, respectively. Apoptosis was not a prominent feature of uterine leiomyomas or myometrium. PCNA- and Ki-67-labeling and mitotic counts were significantly ( P<0.05) higher in leiomyomas than in matched myometrial samples. Proliferative activity was variable for individual tumors of the same patient and independent of tumor size. Our results suggest that altered apoptosis by overexpression of Bcl-2 or by decreased expression of Bax does not appear to be a major factor in uterine leiomyoma growth. We conclude that increased cell proliferation is the most significant contributor to growth and that the proliferative state is autonomous for each tumor in a given patient and is independent of tumor size.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111201     DOI: 10.1007/s00428-001-0568-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  22 in total

1.  An endocrine-disrupting chemical, fenvalerate, induces cell cycle progression and collagen type I expression in human uterine leiomyoma and myometrial cells.

Authors:  Xiaohua Gao; Linda Yu; Lysandra Castro; Alicia B Moore; Tonia Hermon; Carl Bortner; Maria Sifre; Darlene Dixon
Journal:  Toxicol Lett       Date:  2010-03-15       Impact factor: 4.372

2.  1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model.

Authors:  Sunil K Halder; Chakradhari Sharan; Ayman Al-Hendy
Journal:  Biol Reprod       Date:  2012-04-19       Impact factor: 4.285

3.  Immunoexpression of Steroid Hormone Receptors and Proliferation Markers in Uterine Leiomyoma and Normal Myometrial Tissues from the Miniature Pig, Sus scrofa.

Authors:  Kristie Mozzachio; Alicia B Moore; Grace E Kissling; Darlene Dixon
Journal:  Toxicol Pathol       Date:  2015-12-20       Impact factor: 1.902

4.  Hypovitaminosis D exacerbates the DNA damage load in human uterine fibroids, which is ameliorated by vitamin D3 treatment.

Authors:  Mohamed Ali; Sara Mahmoud Shahin; Nagwa Ali Sabri; Ayman Al-Hendy; Qiwei Yang
Journal:  Acta Pharmacol Sin       Date:  2018-11-26       Impact factor: 6.150

5.  Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation.

Authors:  Erica N Nierth-Simpson; Melvenia M Martin; Tung-Chin Chiang; Lilia I Melnik; Lyndsay V Rhodes; Shannon E Muir; Matthew E Burow; John A McLachlan
Journal:  Endocrinology       Date:  2009-01-29       Impact factor: 4.736

6.  Gene therapy targeting leiomyoma: adenovirus-mediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model.

Authors:  Memy H Hassan; Salama A Salama; Dong Zhang; Hossam M M Arafa; Farid M A Hamada; Hala Fouad; Cheryl C Walker; Ayman Al-Hendy
Journal:  Fertil Steril       Date:  2009-01-14       Impact factor: 7.329

7.  Estrogen receptor alpha (ERalpha) phospho-serine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium.

Authors:  Tonia L Hermon; Alicia B Moore; Linda Yu; Grace E Kissling; Frank J Castora; Darlene Dixon
Journal:  Virchows Arch       Date:  2008-10-14       Impact factor: 4.064

8.  Halofuginone suppresses growth of human uterine leiomyoma cells in a mouse xenograft model.

Authors:  Faezeh Koohestani; Wenan Qiang; Amy L MacNeill; Stacy A Druschitz; Vanida A Serna; Malavika Adur; Takeshi Kurita; Romana A Nowak
Journal:  Hum Reprod       Date:  2016-04-29       Impact factor: 6.918

9.  Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas.

Authors:  Linda Yu; Katrin Saile; Carol D Swartz; Hong He; Xiaolin Zheng; Grace E Kissling; Xudong Di; Shantelle Lucas; Stanley J Robboy; Darlene Dixon
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

10.  Towards fibroid gene therapy: adenovirus-mediated delivery of herpes simplex virus 1 thymidine kinase gene/ganciclovir shrinks uterine leiomyoma in the Eker rat model.

Authors:  Memy Hassan; Dong Zhang; Salama Salama; Farid Hamada; Hossam Arafa; Hala Fouad; Cheryl Walker; Ayman Al-Hendy
Journal:  Gynecol Obstet Invest       Date:  2009-03-27       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.